[1]沙宇菁,李彦彦,杨玲.白脂素与2型糖尿病及其血管并发症的研究进展[J].国际内分泌代谢杂志,2021,41(02):133-137.[doi:10.3760/cma.j.cn121383-20200603-06007]
 Sha Yujing,Li Yanyan,Yang Ling.Research progress of asprosin in type 2 diabetes mellitus and its vascular complications[J].International Journal of Endocrinology and Metabolism,2021,41(02):133-137.[doi:10.3760/cma.j.cn121383-20200603-06007]
点击复制

白脂素与2型糖尿病及其血管并发症的研究进展()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年02期
页码:
133-137
栏目:
综述
出版日期:
2021-03-20

文章信息/Info

Title:
Research progress of asprosin in type 2 diabetes mellitus and its vascular complications
作者:
沙宇菁李彦彦杨玲
江苏大学附属医院内分泌代谢科,镇江 212000
Author(s):
Sha Yujing Li Yanyan Yang Ling
Department of Endocrinology, Affiliated Hospital of Jiangsu University, Zhenjiang 212000, China
关键词:
白脂素 2型糖尿病 糖尿病大血管并发症 糖尿病微血管并发症
Keywords:
Asprosin Type 2 diabetes Diabetic macrovascular diseases Diabetic microvascular diseases
DOI:
10.3760/cma.j.cn121383-20200603-06007
摘要:
白脂素(asprosin)是一种新型葡萄糖调控蛋白激素,其主要由白色脂肪细胞合成分泌。Asprosin可通过增强胰岛素抵抗、调节胰岛素分泌、影响食欲参与糖脂代谢,从而调节血糖稳态。此外,研究发现Asprosin与糖尿病大血管并发症及糖尿病微血管并发症存在较多联系,但具体机制尚不清楚。深入探讨Asprosin与糖尿病及其血管并发症的作用机制,可为糖尿病及其血管并发症的治疗提供新靶点。
Abstract:
Asprosin is a new type of glucose regulatory protein hormone, which is mainly synthesized and secreted by white adipocytes. Asprosin can regulate glucose homeostasis by enhancing insulin resistance, regulating insulin secretion and affecting appetite. In addition, studies have found that asprosin is associated with diabetic macrovascular complications and diabetic microvascular complications, but the specific mechanism is not clear. In order to provide a new target for the treatment of diabetes mellitus and its vascular complications, the mechanism of asprosin in diabetes mellitus and its vascular complications should be explored.

参考文献/References:

[1] Li Y,Teng D,Shi X,et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study[J].BMJ,2020,369:m997.DOI:10.1136/bmj.m997.
[2] Romere C,Duerrschmid C,Bournat J,et al. Asprosin,a fasting-induced glucogenic protein hormone[J].Cell,2016,165(3):566-579.DOI:10.1016/j.cell.2016.02.063.
[3] Duerrschmid C,He Y,Wang C,et al. Asprosin is a centrally acting orexigenic hormone[J].Nat Med,2017,23(12):1444-1453.DOI:10.1038/nm.4432.
[4] 朱丽雯,谭延振,罗文平,等. Asprosin的表达纯化及其对小鼠在体心脏功能的作用[J].中国实验动物学报,2017,25(04):368-372,379.DOI:10.3969/j.issn.1005-4847.2017.04.005.
[5] Ugur K,Aydin S. Saliva and blood asprosin hormone concentration associated with obesity[J].Int J Endocrinol,2019,2019:2521096.DOI:10.1155/2019/2521096.
[6] Ko JR,Seo DY,Kim TN,et al. Aerobic exercise training decreases hepatic asprosin in diabetic rats[J].J Clin Med,2019,8(5):666.DOI:10.3390/jcm8050666.
[7] Ozcan S,Ulker N,Bulmus O,et al. The modulatory effects of irisin on asprosin,leptin,glucose levels and lipid profile in healthy and obese male and female rats[J].Arch Physiol Biochem,2020,1-8.DOI:10.1080/13813455.2020.1722706.
[8] Liu Y,Long A,Chen L,et al. The Asprosin-OLFR734 module regulates appetitive behaviors?[J].Cell Discov,2020,6:19.DOI:10.1038/s41421-020-0152-4.
[9] Zhang Z,Tan Y,Zhu L,et al. Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway[J].Life Sci,2019,231:116554.DOI:10.1016/j.lfs.2019.116554.
[10] Lee T,Yun S,Jeong JH,et al. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation[J].Mol Cell Endocrinol,2019,486:96-104.DOI:10.1016/j.mce.2019.03.001.
[11] Jung TW,Kim HC,Kim HU,et al. Asprosin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in skeletal muscle[J].J Cell Physiol,2019,234(11):20888-20899.DOI:10.1002/jcp.28694.
[12] Li E,Shan H,Chen L,et al. OLFR734 mediates glucose metabolism as a receptor of asprosin[J].Cell Metab,2019,30(2):319-328.e8.DOI:10.1016/j.cmet.2019.05.022.
[13] Wang Y,Qu H,Xiong X,et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion[J].Mediators Inflamm,2018,2018:9471583.DOI:10.1155/2018/9471583.
[14] Hu Y,Xu Y,Zheng Y,et al. Increased plasma asprosin levels in patients with drug-naive anorexia nervosa[J].Eat Weight Disord,2020,26(1):313-321.DOI:10.1007/s40519-020-00845-3.
[15] Zhang X,Jiang H,Ma X,et al. Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type?2 diabetes mellitus[J].J Diabtes Investig,2020,11(2):349-355.DOI:10.1111/jdi.13148.
[16] Acara AC,Bolatkale M,Kzlogˇlu I·,et al. A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris:asprosin[J].Am J Emerg Med,2018,36(8):1504-1505.DOI:10.1016/j.ajem.2017.12.032.
[17] 徐佰达,叶挺,王倩,等.血浆白脂素水平与冠心病的关系[J].心脏杂志,2019,31(4):428-431.DOI:10.12125/j.chj.201902048.
[18] 夏虹,李昊翔,徐梦娇,等.2型糖尿病患者血清Asprosin水平与颈动脉内中膜厚度的关系[J].江苏大学学报(医学版),2020,30(3):248-252.DOI:10.13312/j.issn.1671-7783.y200056.
[19] 李昊翔,徐梦娇,袁婧,等. 2型糖尿病合并非酒精性脂肪肝患者血清白脂素浓度变化及其影响因素[J].江苏大学学报(医学版),2019,29(01):62-66.DOI:10.13312/j.issn.1671-7783.y180227.
[20] 陈莎,汪雄,邱琛茗,等. Spartin和白脂素在糖尿病心脏微血管内皮损伤中的作用及其机制探讨[J].四川大学学报(医学版),2019,50(6):827-834.DOI:10.13464/j.scuxbyxb.2019.06.009.
[21] 冯健,杜劲,侯娟妮,等.白脂素对高糖导致的心肌细胞损伤保护作用的研究[J].中国糖尿病杂志,2018,26(9):775-779.DOI:10.3969/j.issn.1006-6187.2018.09.013.
[22] EI-Kattawy HA,WMR Ashour. Anti-asprosin:a potential protective role against the progression of diabetic nephropathy in type 2 diabetic rats[J].Am J Biomed Sci,2019,11(3):183-199.DOI:10.5099/aj190300183.
[23] Zhang H,Hu W,Zhang G. Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease[J].Int Urol Nephrol,2020,52(8):1517-1522.DOI:10.1007/s11255-020-02509-8.
[24] Oruc Y,Celik F,Ozgur G,et al. Altered blood and aqueous humor levels of asprosin 4-hydroxynonenal,and 8-hydroxy-deoxyguanosine in patients with diabetes mellitus and cataract with and without diabetic retionpathy[J].Retina,2020,40(12):2410-2416.DOI:10.1097/IAE.0000000000002776.
[25] 黄庆先,胡文超,何兰杰,等. 血清asprosin与糖尿病视网膜病变的相关性研究[J].国际内分泌代谢杂志,2020,40(6):372-375.DOI:10.3760/cma.j.cn121383-20200311-03027.

相似文献/References:

[1]赵紫琴,雒瑢,田凤石,等.替米沙坦对OLETF大鼠皮下和内脏脂肪组织PPARγ表达的影响[J].国际内分泌代谢杂志,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
 Zhao Ziqin*,Luo Rong,Tian Fengshi,et al.Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats[J].International Journal of Endocrinology and Metabolism,2014,(02):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
[2]姚霜霜,张翼飞,张志国,等.小檗碱改善代谢性疾病的肠道相关机制[J].国际内分泌代谢杂志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
 Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(02):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[3]曹萌 韦晓 刘超.自噬与胰岛β细胞功能及2型糖尿病[J].国际内分泌代谢杂志,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
 Cao Meng,Wei Xiao,Liu Chao..Relationship between autophagy and islet β cells function, type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(02):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
[4]刘艳 田秀标 韩颖.GLP-1受体激动剂呈葡萄糖依赖性刺激胰岛β细胞胰岛素分泌的机制[J].国际内分泌代谢杂志,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
 Liu Yan*,Tian Xiubiao,Han Ying..Mechanism of GLP-1 receptor agonists in the stimulation of insulin secretion of islet β cell in a glucose-dependent manner[J].International Journal of Endocrinology and Metabolism,2015,(02):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
[5]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
 Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(02):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[6]梅稳,向光大,卢俊颜,等.GDF11对ApoE-/-糖尿病小鼠内皮依赖性 血管舒张功能的作用[J].国际内分泌代谢杂志,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
 Mei Wen*,Xiang Guangda,Lu Junyan,et al.Effects of GDF11 on endothelium-dependent vasodiation function of aorta in ApoE-/- diabetic mice[J].International Journal of Endocrinology and Metabolism,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
[7]殷俏,张云良,郭淑芹,等.视黄醇结合蛋白4、超敏C反应蛋白 与糖尿病视网膜病变的关系[J].国际内分泌代谢杂志,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
 Yin Qiao,Zhang Yunliang,Guo Shuqin,et al.Relationship of retinol binding protein 4 and high sensitive C-reactive protein with diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2016,36(02):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
[8]王涛,张洁,祁范范,等.不同糖耐量人群血清25(OH)D3水平 及与胰岛β细胞功能的关系[J].国际内分泌代谢杂志,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
 Wang Tao*,Zhang Jie,Qi Fanfan,et al.Relationship between serum 25(OH)D3 level and islet β cell function in individuals with different glucose tolerance[J].International Journal of Endocrinology and Metabolism,2016,36(02):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
[9]陈双双,王楚媛,孔令芳.铬与2型糖尿病[J].国际内分泌代谢杂志,2016,36(04):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
 Chen Shuangshuang,Wang Chuyuan,Kong Lingfang.Chromium and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2016,36(02):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
[10]涂萍,许婷,段鹏,等.25-羟维生素D3补充对绝经后2型糖尿病 患者胰岛素敏感性及血糖控制的影响[J].国际内分泌代谢杂志,2016,36(05):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]
 Tu Ping,Xu Ting,Duan Peng,et al.Influence of 25-hydroxyvitamin D3 supplement on insulin sensitivity and glucose control in postmenopausal patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(02):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]
[11]何桥玲 陈桂兰 陈家琪 张振 孙嘉 陈宏.白脂素在2型糖尿病发生及发展中的作用[J].国际内分泌代谢杂志,2020,40(04):267.[doi:10.3760/cma.j.issn.1673-4157.2020.04.012]
 He Qiaoling,Chen Guilan,Chen Jiaqi,et al.Roles of asprosin in the occurence and development of type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2020,40(02):267.[doi:10.3760/cma.j.issn.1673-4157.2020.04.012]

备注/Memo

备注/Memo:
通信作者:杨玲,Email:1027322959@qq.com 基金项目:江苏省预防医学科研课题(Y2018109)
更新日期/Last Update: 2021-03-20